Literature DB >> 3118117

Immunofluorescence labeling indices in myeloma and related monoclonal gammopathies.

P R Greipp1, T E Witzig, N J Gonchoroff, T M Habermann, J A Katzmann, W M O'Fallon, R A Kyle.   

Abstract

We measured plasma cell labeling indices (LI) in 52 patients with monoclonal gammopathies. Cytoplasmic reactivity with polyspecific or kappa- and lambda-specific light chain anti-Ig reagents identified monoclonal plasma cells, plasmablasts, and lymphocytoid plasma cells. Among newly diagnosed untreated patients, a high immunofluorescence LI distinguished those with multiple myeloma (MM) from those with stable monoclonal gammopathies (P less than 0.002). Among treated patients with MM, those in the plateau phase of the disease had low LI, whereas patients in the relapse phase or early in treatment had high LI. The immunofluorescence LI correctly classified three more patients with newly diagnosed MM than did the tritiated thymidine LI technique. LI specific for the neoplastic plasma cells resulted in excellent discrimination of patients with active disease. Because results are easily and rapidly obtained, this technique is useful clinically.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3118117     DOI: 10.1016/s0025-6196(12)65066-6

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  12 in total

1.  The albumin and monoclonal protein ratio as prognostic marker for multiple myeloma in the era of novel agents.

Authors:  Katalin Kádár; Krisztina Wolf; Judit Tábori; István Karádi; Judit Várkonyi
Journal:  Pathol Oncol Res       Date:  2012-07       Impact factor: 3.201

2.  Use of cytoplasmic 5'nucleotidase for differentiating malignant from benign monoclonal gammopathies.

Authors:  G Majumdar; S E Heard; A K Singh
Journal:  J Clin Pathol       Date:  1990-11       Impact factor: 3.411

3.  Reduction in plasma cell proliferation after initial therapy in newly diagnosed multiple myeloma measures treatment response and predicts improved survival.

Authors:  Jeremy T Larsen; Cheng E Chee; John A Lust; Philip R Greipp; S Vincent Rajkumar
Journal:  Blood       Date:  2011-07-12       Impact factor: 22.113

4.  Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis.

Authors:  M A Gertz; M Q Lacy; J A Lust; P R Greipp; T E Witzig; R A Kyle
Journal:  Med Oncol       Date:  1999-07       Impact factor: 3.064

5.  CD19 and immunophenotype of bone marrow plasma cells in monoclonal gammopathy of undetermined significance.

Authors:  M Zandecki; T Facon; F Bernardi; V Izydorczyk; L Dupond; M François; R Reade; T Iaru; F Bauters; A Cosson
Journal:  J Clin Pathol       Date:  1995-06       Impact factor: 3.411

Review 6.  Immunophenotyping in multiple myeloma and related plasma cell disorders.

Authors:  Shaji Kumar; Teresa Kimlinger; William Morice
Journal:  Best Pract Res Clin Haematol       Date:  2010-09       Impact factor: 3.020

7.  Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma.

Authors:  Dirk Hose; Thierry Rème; Thomas Hielscher; Jérôme Moreaux; Tobias Messner; Anja Seckinger; Axel Benner; John D Shaughnessy; Bart Barlogie; Yiming Zhou; Jens Hillengass; Uta Bertsch; Kai Neben; Thomas Möhler; Jean François Rossi; Anna Jauch; Bernard Klein; Hartmut Goldschmidt
Journal:  Haematologica       Date:  2010-09-30       Impact factor: 9.941

Review 8.  Smoldering multiple myeloma and monoclonal gammopathy of undetermined significance.

Authors:  Joan Bladé; Laura Rosiñol
Journal:  Curr Treat Options Oncol       Date:  2006-05

9.  Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component.

Authors:  John A Lust; Martha Q Lacy; Steven R Zeldenrust; Angela Dispenzieri; Morie A Gertz; Thomas E Witzig; Shaji Kumar; Suzanne R Hayman; Stephen J Russell; Francis K Buadi; Susan M Geyer; Megan E Campbell; Robert A Kyle; S Vincent Rajkumar; Philip R Greipp; Michael P Kline; Yuning Xiong; Laurie L Moon-Tasson; Kathleen A Donovan
Journal:  Mayo Clin Proc       Date:  2009-02       Impact factor: 7.616

10.  Plasma cell proliferation in monoclonal gammopathies: measurement using BU-1 antibody in flow cytometry and microscopy: comparison with serum thymidine kinase.

Authors:  C M Schambeck; M Wick; R Bartl; R Lamerz; A Fateh-Moghadam
Journal:  J Clin Pathol       Date:  1995-05       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.